JP2017524670A - 鉄欠乏症の治療方法 - Google Patents
鉄欠乏症の治療方法 Download PDFInfo
- Publication number
- JP2017524670A JP2017524670A JP2016573503A JP2016573503A JP2017524670A JP 2017524670 A JP2017524670 A JP 2017524670A JP 2016573503 A JP2016573503 A JP 2016573503A JP 2016573503 A JP2016573503 A JP 2016573503A JP 2017524670 A JP2017524670 A JP 2017524670A
- Authority
- JP
- Japan
- Prior art keywords
- group
- iron oxide
- biocompatible
- oxide nanoparticles
- particle size
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010022971 Iron Deficiencies Diseases 0.000 title claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 40
- 229940031182 nanoparticles iron oxide Drugs 0.000 claims abstract description 30
- 229920000249 biocompatible polymer Polymers 0.000 claims abstract description 25
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical group [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 claims abstract description 20
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical group [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 10
- 125000003827 glycol group Chemical group 0.000 claims abstract description 9
- -1 aliphatic radical Chemical class 0.000 claims description 36
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 claims description 24
- 239000002245 particle Substances 0.000 claims description 17
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 229910052717 sulfur Inorganic materials 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 125000002947 alkylene group Chemical group 0.000 claims description 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 8
- 125000005647 linker group Chemical group 0.000 claims description 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 4
- 125000006353 oxyethylene group Chemical group 0.000 claims description 4
- 150000005840 aryl radicals Chemical class 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 229910052710 silicon Inorganic materials 0.000 claims description 3
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 2
- 150000003254 radicals Chemical class 0.000 claims 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 68
- 229910052742 iron Inorganic materials 0.000 description 34
- 241000700159 Rattus Species 0.000 description 26
- 150000004676 glycans Chemical class 0.000 description 19
- 229920001282 polysaccharide Polymers 0.000 description 19
- 239000005017 polysaccharide Substances 0.000 description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 125000000217 alkyl group Chemical group 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 108010058846 Ovalbumin Proteins 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 229940092253 ovalbumin Drugs 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 229920001427 mPEG Polymers 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 229910000077 silane Inorganic materials 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 229940014800 succinic anhydride Drugs 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical group C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- NJFMNPFATSYWHB-UHFFFAOYSA-N ac1l9hgr Chemical compound [Fe].[Fe] NJFMNPFATSYWHB-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 239000002122 magnetic nanoparticle Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000005551 pyridylene group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 230000011506 response to oxidative stress Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 1
- OBDUMNZXAIUUTH-HWKANZROSA-N (e)-tetradec-2-ene Chemical group CCCCCCCCCCC\C=C\C OBDUMNZXAIUUTH-HWKANZROSA-N 0.000 description 1
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N 1-Heptene Chemical group CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
- VQOXUMQBYILCKR-UHFFFAOYSA-N 1-Tridecene Chemical group CCCCCCCCCCCC=C VQOXUMQBYILCKR-UHFFFAOYSA-N 0.000 description 1
- AFFLGGQVNFXPEV-UHFFFAOYSA-N 1-decene Chemical group CCCCCCCCC=C AFFLGGQVNFXPEV-UHFFFAOYSA-N 0.000 description 1
- CRSBERNSMYQZNG-UHFFFAOYSA-N 1-dodecene Chemical group CCCCCCCCCCC=C CRSBERNSMYQZNG-UHFFFAOYSA-N 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N 1-nonene Chemical group CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- KWKAKUADMBZCLK-UHFFFAOYSA-N 1-octene Chemical group CCCCCCC=C KWKAKUADMBZCLK-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- 125000005865 C2-C10alkynyl group Chemical group 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- CZNVSLGYWMSMKE-OPDGVEILSA-K Ferric gluconate Chemical compound [Fe+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O CZNVSLGYWMSMKE-OPDGVEILSA-K 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005277 alkyl imino group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 125000004653 anthracenylene group Chemical group 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000004467 aryl imino group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000005724 cycloalkenylene group Chemical group 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000004986 diarylamino group Chemical group 0.000 description 1
- FWZTTZUKDVJDCM-CEJAUHOTSA-M disodium;(2r,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;iron(3+);oxygen(2-);hydroxide;trihydrate Chemical compound O.O.O.[OH-].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FWZTTZUKDVJDCM-CEJAUHOTSA-M 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 125000005567 fluorenylene group Chemical group 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940096010 iron polysaccharide Drugs 0.000 description 1
- 229940032961 iron sucrose Drugs 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000001802 myricyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- GQEZCXVZFLOKMC-UHFFFAOYSA-N n-alpha-hexadecene Natural products CCCCCCCCCCCCCCC=C GQEZCXVZFLOKMC-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004957 naphthylene group Chemical group 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- LHKVDVFVJMYULK-UHFFFAOYSA-N nitrosylazide Chemical compound [N-]=[N+]=NN=O LHKVDVFVJMYULK-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000005564 oxazolylene group Chemical group 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- 125000005548 pyrenylene group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000005557 thiazolylene group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000005556 thienylene group Chemical group 0.000 description 1
- 125000003441 thioacyl group Chemical group 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
これらの実施形態の2種の生体適合性の酸化鉄ナノ粒子を、以下に記載される手順に従って製造した。
FeCl2・4H2O(11.6g、0.058モル)、FeCl3・6H2O(11.6g、0.096モル)及び水(400mL)の混合物を、三ツ口フラスコ内にて25℃、300rpmで撹拌した。そのフラスコに、水酸化ナトリウム溶液(2.5N、170mL)を47μl/秒の速度で添加することで、11〜12のpH値が得られた。引き続き、オレイン酸(20mL)を添加し、30分間にわたり撹拌し、引き続き6NのHCl溶液を添加することで、pH値を約1へと調整した。該混合物からこうして析出した酸化鉄コアを濾過により回収し、水で4回又は5回にわたり洗浄して、過剰のオレイン酸を除去した。次いでこうして得られた酸化鉄コアを真空下で乾燥させて、以下に記載されるようにして、生体適合性ポリマーとのカップリングのために使用した。
生体適合性ポリマーのmPEG−シラン−750を、以下に記載される手順に従って製造した。
こうして得られた生体適合性ポリマーのmPEG−シラン−750及びmPEG−シラン−2000のそれぞれ(250g)を、上記の通りに製造した酸化鉄コア10gを含有する1L〜1.2Lのトルエン溶液中に懸濁した。その懸濁液を24時間にわたり撹拌し、引き続き水(1.5L)を添加して抽出を行った。抽出された水溶液を限外濾過装置で濾過し、水で洗浄し、次いで100mLにまで濃縮することで、生体適合性の酸化鉄ナノ粒子の懸濁液が得られた。該酸化鉄ナノ粒子は、mPEG−シラン−750から製造されたか、mPEG−シラン−2000から製造されたかにかかわらず、iTrastと呼ぶ。
こうして得られた生体適合性の磁性ナノ粒子iTrastの透過電子顕微鏡法(TEM)画像を、JEOL社製JEM−2100F型電界放出形透過電子顕微鏡法を用いて撮影した。それらの画像により、iTrastが10nm〜12nmの寸法の酸化鉄コアを有することが裏付けられた。
IDAの治療におけるiTrast及び多糖類鉄の効能及び安全性を、以下に記載される手順に従って比較した。
鉄欠乏は、30匹の離乳スプラーグ−ドーリーラット(それぞれ50g〜70g、Zivic-Miller、ペンシルヴェニア州アリソンパーク)に鉄欠乏飼料(Low Iron Diet、ICN Nutritional Biochemicals、オハイオ州クリーヴランド)を与えることによって引き起こした。8匹の対照ラット(モック群)には、標準飼料(Purina Rat Chow、Ralston Purina、ミズーリ州セントルイス)を与えた。全てのラットを、ステンレス鋼製の屋根を備えたポリエチレン製の檻に入れた。約3週間で、30匹のIDAラットのヘモグロビン(Hb)濃度は、約16g/dLから約6g/dLへと下がった。該Hb濃度は、「栄養と代謝の内側(Nutrition and Metabolic Insights)」2014:7 1-6に記載される手順に従って求めた。
BALB/cマウス(国家実験動物センター(The National Laboratory Animal Center)、台北)を、オボアルブミン(OVA)及び不完全フロイントアジュバント(IFA)で感作させた。7日目に、これらのマウスに、0.1mg/kgのOVA、12mg/kgの多糖類鉄又は12mg/kgのiTrastを負荷した。負荷24時間後に足の腫脹厚さを測定した。OVA負荷したマウス、多糖類鉄負荷したマウス及びiTrast負荷したマウスは、それぞれ0.42mm、0.20mm及び0.08mmの足の腫脹厚さを有していた。それらの結果は、(1)OVA負荷したマウスが、その他のマウスよりも重度の腫脹を足に有すること、及び(2)多糖類鉄負荷が、iTrast負荷よりもかなり大きな腫脹厚さを足に誘発することを裏付けており、このことは、iTrastが、予想外にも多糖類鉄よりも安全であることを示している。
IDAラット(国家実験動物センター、台北)に、12mg/kgのiTrast又は多糖類鉄を静脈注射した。23日目に、酸化ストレス応答の試験のために、それらのラットを屠殺し、脾臓を採取し、脾細胞を単離した。市販キット、すなわち総ROS/スーパーオキシド検出キット(Total ROS/Superoxide detection kit)(ENZ−51010;Enzo Life Sciences,Inc.、ニューヨーク州)を使用して、リアルタイムの生細胞における活性酸素種及びスーパーオキシドの全体レベルを測定した。
IDAラット(国家実験動物センター、台北)に、12mg/kgのiTrast又は多糖類鉄を静脈注射した。23日目に、2つの群、すなわち多糖類鉄処理群及びiTrast処理群のそれぞれのラットから血液を採収し、そこから血清を調製し、遊離鉄濃度を、Expert Rev Hematol. 2012;5:229-241及び「栄養と代謝の内側」2014:7 1-6に記載される手順に従って求めた。
本明細書で開示された特徴は全てあらゆる組合せで組み合わせることができる。本明細書で開示される各特徴は同じ、同等の、又は同様の目的を果たす代替特徴に置き換えることができる。そのため特に明記しない限り、開示される各特徴は一連の包括的な同等又は同様の特徴の例にすぎない。
Claims (22)
- 鉄欠乏に関連した状態を治療する方法であって、該方法が、
鉄欠乏に関連した状態を持つ患者を特定することと、
該患者に有効量の生体適合性の酸化鉄ナノ粒子を投与することと、
を含み、前記生体適合性の酸化鉄ナノ粒子は、それぞれ1種以上の生体適合性ポリマーによって覆われた酸化鉄コアを含み、そのそれぞれは、ポリエチレングリコール基、シラン基及びポリエチレングリコール基とシラン基とを共有結合を介して連結するリンカーを有する、方法。 - 前記状態は、鉄欠乏性貧血である、請求項1に記載の方法。
- 前記酸化鉄コアは、2nm〜50nmの粒径を有し、前記ポリエチレングリコール基は、5個〜1000個のオキシエチレン単位を有し、前記シラン基は、C1〜10アルキレン基を含み、かつ前記リンカーは、O、S、Si、C1〜C6アルキレン、2個のカルボニル基及び2個〜20個の炭素原子を含むカルボニル部、又は以下の式:
- 前記生体適合性の酸化鉄ナノ粒子は、それぞれ3nm〜1000nmの粒径を有する、請求項3に記載の方法。
- 前記生体適合性の酸化鉄ナノ粒子は、それぞれ15nm〜200nmの粒径を有する、請求項4に記載の方法。
- 前記状態は、鉄欠乏性貧血である、請求項5に記載の方法。
- 前記酸化鉄コアは、2nm〜50nmの粒径を有し、前記ポリエチレングリコール基は、10個〜200個のオキシエチレン単位を有し、前記シラン基は、C3〜C10アルキレンを含み、かつ前記リンカーは、以下の式:
- 前記生体適合性の酸化鉄ナノ粒子は、それぞれ3nm〜1000nmの粒径を有する、請求項7に記載の方法。
- 前記生体適合性の酸化鉄ナノ粒子は、それぞれ15nm〜200nmの粒径を有する、請求項8に記載の方法。
- 前記状態は、鉄欠乏性貧血である、請求項9に記載の方法。
- 前記生体適合性の酸化鉄ナノ粒子は、それぞれ3nm〜1000nmの粒径を有する、請求項1に記載の方法。
- 前記生体適合性の酸化鉄ナノ粒子は、それぞれ15nm〜200nmの粒径を有する、請求項11に記載の方法。
- 前記酸化鉄コアは、以下の式:
RはH、C1〜C6アルキル基、C2〜C6アルケニル基、C2〜C6アルキニル基、C3〜C10シクロアルキル基、C1〜C10ヘテロシクロアルキル基、アリール基、ヘテロアリール基、C1〜C10カルボニル基、又はC1〜C10アミン基であり、
Lはリンカーであり、
mは1〜10であり、かつ、
nは5〜1000である)を有する1種以上の生体適合性ポリマーによって覆われている、請求項1に記載の方法。 - 前記リンカーは、O、S、Si、C1〜C6アルキレン、2個のカルボニル基及び2個〜20個の炭素原子を含むカルボニル部、又は以下の式:
- 前記酸化鉄コアは、以下の式:
R1はH、C1〜C6アルキル基、C2〜C6アルケニル基、C2〜C6アルキニル基、C3〜C10シクロアルキル基、C1〜C10ヘテロシクロアルキル基、アリール基、ヘテロアリール基、C1〜C10カルボニル基、又はC1〜C10アミン基であり、
R2はH、C1〜C6アルキル、C2〜C6アルケニル、C2〜C6アルキニル、C3〜C10シクロアルキル、C1〜C10ヘテロシクロアルキル、アリール又はヘテロアリールであり、
mは1〜10であり、かつ、
nは5〜1000である)を有する1種以上の生体適合性ポリマーによって覆われている、請求項1に記載の方法。 - 前記生体適合性の酸化鉄ナノ粒子は、それぞれ3nm〜1000nmの粒径を有する、請求項15に記載の方法。
- 前記生体適合性の酸化鉄ナノ粒子は、それぞれ15nm〜200nmの粒径を有する、請求項16に記載の方法。
- 前記状態は、鉄欠乏性貧血である、請求項17に記載の方法。
- R1はHであり、R2はH、C1〜C6アルキル基、C1〜C10カルボニル基又はC1〜C10アミン基であり、mは3〜10であり、かつnは10〜200である、請求項15に記載の方法。
- 前記生体適合性の酸化鉄ナノ粒子は、それぞれ3nm〜1000nmの粒径を有する、請求項19に記載の方法。
- 前記生体適合性の酸化鉄ナノ粒子は、それぞれ15nm〜200nmの粒径を有する、請求項20に記載の方法。
- 前記状態は、鉄欠乏性貧血である、請求項21に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462023533P | 2014-07-11 | 2014-07-11 | |
US62/023,533 | 2014-07-11 | ||
PCT/CN2015/083765 WO2016004894A1 (en) | 2014-07-11 | 2015-07-10 | Method of treating iron deficiency |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017524670A true JP2017524670A (ja) | 2017-08-31 |
JP2017524670A5 JP2017524670A5 (ja) | 2018-08-16 |
JP6630293B2 JP6630293B2 (ja) | 2020-01-15 |
Family
ID=53773226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016573503A Active JP6630293B2 (ja) | 2014-07-11 | 2015-07-10 | 鉄欠乏症の治療方法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US9492399B2 (ja) |
EP (1) | EP2965754B1 (ja) |
JP (1) | JP6630293B2 (ja) |
CN (1) | CN107073035B (ja) |
ES (1) | ES2654429T3 (ja) |
HU (1) | HUE035242T2 (ja) |
PL (1) | PL2965754T3 (ja) |
PT (1) | PT2965754T (ja) |
TW (1) | TWI689310B (ja) |
WO (1) | WO2016004894A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110157000B (zh) * | 2018-02-12 | 2022-05-31 | 巨生生医股份有限公司 | 生物相容性磁性材料 |
WO2024100213A1 (fr) | 2022-11-10 | 2024-05-16 | Université De Lorraine | Nanoclusters de fer, leurs procédés d'obtention et leurs utilisations pour lutter contre les carences en fer |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5248492A (en) | 1986-07-03 | 1993-09-28 | Advanced Magnetics, Inc. | Low molecular weight carbohydrates as additives to stabilize metal oxide compositions |
US5554386A (en) | 1986-07-03 | 1996-09-10 | Advanced Magnetics, Inc. | Delivery of therapeutic agents to receptors using polysaccharides |
US7871597B2 (en) | 1999-04-09 | 2011-01-18 | Amag Pharmaceuticals, Inc. | Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents |
EP1169062B1 (en) | 1999-04-09 | 2009-10-21 | AMAG Pharmaceuticals, Inc. | Heat stable coated colloidal iron oxides |
US6997863B2 (en) * | 2001-07-25 | 2006-02-14 | Triton Biosystems, Inc. | Thermotherapy via targeted delivery of nanoscale magnetic particles |
US20030190355A1 (en) | 2002-04-05 | 2003-10-09 | Hermelin Marc S. | Modified release minerals |
US7462446B2 (en) | 2005-03-18 | 2008-12-09 | University Of Washington | Magnetic nanoparticle compositions and methods |
AU2006282042B2 (en) | 2005-06-17 | 2011-12-22 | The University Of North Carolina At Chapel Hill | Nanoparticle fabrication methods, systems, and materials |
DE102005059751A1 (de) | 2005-12-09 | 2007-06-14 | Ferropharm Gmbh Forschungslabor | Wässrige Dispersion von superparamagnetischen Eindomänenteilchen, deren Herstellung und Verwendung zur Diagnose und Therapie |
TWI293113B (en) | 2005-12-23 | 2008-02-01 | Ind Tech Res Inst | Magnetic nanoparticles with fluorescent and specific targeting functions |
CN101365458B (zh) | 2006-01-06 | 2012-09-05 | 卢特波尔德药品公司 | 用于铁给药的方法和组合物 |
TW200819540A (en) | 2006-07-11 | 2008-05-01 | Genelux Corp | Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders |
TWI321133B (en) | 2006-08-01 | 2010-03-01 | Univ Kaohsiung Medical | Folate-receptor-targeting iron oxide nanoparticles coated with poly(ethylene glycol) |
ES2308901B1 (es) | 2006-09-22 | 2009-10-30 | Consejo Superior De Investigaciones Cientificas | Sistemas que contienen nanoparticulas magneticas y polimeros, como nanocomposites y ferrofluidos, y sus aplicaciones. |
US20110104073A1 (en) | 2007-01-18 | 2011-05-05 | Qi Zeng | Iron/Iron Oxide Nanoparticle and Use Thereof |
US20120003160A1 (en) | 2007-06-29 | 2012-01-05 | Amag Pharmaceuticals, Inc. | Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session |
TWI361082B (en) | 2008-01-15 | 2012-04-01 | Ind Tech Res Inst | Biocompatible polymer and magnetic nanoparticle with biocompatibilities |
WO2009120702A2 (en) | 2008-03-25 | 2009-10-01 | Emory University | Elemental iron nanoparticles |
HUE049091T2 (hu) * | 2008-04-22 | 2020-08-28 | Megapro Biomedical Co Ltd | Biokompatibilis polimer és biokompatibilis tulajdonságú mágneses nanorészecske |
US20090280063A1 (en) | 2008-05-09 | 2009-11-12 | General Electric Company | Novel pei-peg graft copolymer coating of iron oxide nanoparticles for inflammation imaging |
WO2010034319A1 (en) | 2008-09-29 | 2010-04-01 | Innovative Research And Development Co. (Inrad) | Magnetite nanoparticles as a single dose treatment for iron deficiency anemia |
CN102333547A (zh) | 2008-12-29 | 2012-01-25 | 通用电气公司 | 用于诊断成像的纳米颗粒造影剂 |
US8840868B2 (en) | 2009-02-04 | 2014-09-23 | The Regents Of The University Of Colorado, A Body Corporate | Non-invasive detection of complement-mediated inflammation using CR2-targeted nanoparticles |
EP2275137A1 (en) | 2009-07-10 | 2011-01-19 | Nanobiotix | Metallic nanoparticles, preparation and uses thereof |
GB2472446A (en) | 2009-08-07 | 2011-02-09 | Ct Fuer Angewandte Nanotechnologie | Metal oxide particles coated with polyethylene glycol and their synthesis |
WO2011052205A1 (ja) | 2009-10-30 | 2011-05-05 | 国立大学法人東京工業大学 | ポリマー被覆フェライト微粒子および製造方法 |
US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
US20120177700A1 (en) | 2010-12-27 | 2012-07-12 | Imran Mir A | Nanonized Iron Compositions and Methods of Use Thereof |
CN102349930B (zh) | 2011-11-01 | 2013-07-10 | 东南大学 | 具有抗氧化活性的氧化铁纳米粒水凝胶剂 |
US9474810B2 (en) | 2012-03-02 | 2016-10-25 | General Electric Company | Superparamagnetic nanoparticles with PEG substituted α-hydroxy phosphonate shells |
US9196405B2 (en) | 2012-04-03 | 2015-11-24 | Florida State University Research Foundation, Inc. | Stable iron oxide nanoparticles and method of production |
EP2647389A1 (en) * | 2012-04-04 | 2013-10-09 | Charité - Universitätsmedizin Berlin | Magnetic nanoparticle dispersion, its preparation and diagnostic and therapeutic use |
EP2858630A4 (en) | 2012-06-07 | 2016-02-24 | Harvard College | NANOTHERAPEUTIC PRODUCTS FOR DRUG TARGETING |
US20130336897A1 (en) | 2012-06-18 | 2013-12-19 | Gerald L. Wolf | Theranosis of macrophage-associated diseases with ultrasmall superparamagnetic iron oxide nanoparticles (uspio) |
CN103251648B (zh) | 2013-05-15 | 2015-08-05 | 乔敏 | 治疗血磷酸盐过多症及缺铁性贫血症的铁基蒙脱石药物及其制备方法 |
CN103341165B (zh) | 2013-05-31 | 2015-04-01 | 上海师范大学 | 一种具有光热功能的Fe@Fe3O4纳米粒子及其制备方法和应用 |
CN103303981B (zh) | 2013-07-04 | 2015-04-01 | 厦门大学 | 一种四氧化三铁纳米粒子及其制备方法和用途 |
CN103405790B (zh) | 2013-07-15 | 2015-05-20 | 中国科学院过程工程研究所 | 一种高分子原位修饰的超顺磁性颗粒、制备方法及其用途 |
CN103469290B (zh) | 2013-09-02 | 2016-01-13 | 南阳师范学院 | 一种合成超顺磁性Fe3O4纳米晶的方法 |
CN103601900A (zh) | 2013-11-15 | 2014-02-26 | 无锡中科光远生物材料有限公司 | 一种具有靶向效应的纳米颗粒的制备方法 |
-
2015
- 2015-06-29 TW TW104120956A patent/TWI689310B/zh active
- 2015-07-10 CN CN201580035310.XA patent/CN107073035B/zh active Active
- 2015-07-10 US US14/796,332 patent/US9492399B2/en active Active
- 2015-07-10 WO PCT/CN2015/083765 patent/WO2016004894A1/en active Application Filing
- 2015-07-10 JP JP2016573503A patent/JP6630293B2/ja active Active
- 2015-07-12 ES ES15176372.9T patent/ES2654429T3/es active Active
- 2015-07-12 PT PT151763729T patent/PT2965754T/pt unknown
- 2015-07-12 HU HUE15176372A patent/HUE035242T2/en unknown
- 2015-07-12 PL PL15176372T patent/PL2965754T3/pl unknown
- 2015-07-12 EP EP15176372.9A patent/EP2965754B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN107073035B (zh) | 2020-08-28 |
PL2965754T3 (pl) | 2018-04-30 |
TWI689310B (zh) | 2020-04-01 |
US20160008292A1 (en) | 2016-01-14 |
JP6630293B2 (ja) | 2020-01-15 |
EP2965754A1 (en) | 2016-01-13 |
US9492399B2 (en) | 2016-11-15 |
PT2965754T (pt) | 2018-01-08 |
CN107073035A (zh) | 2017-08-18 |
ES2654429T3 (es) | 2018-02-13 |
WO2016004894A1 (en) | 2016-01-14 |
HUE035242T2 (en) | 2018-05-02 |
EP2965754B1 (en) | 2017-10-04 |
TW201625278A (zh) | 2016-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10369113B2 (en) | Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer | |
JP6867084B2 (ja) | 新規な陽イオン性ポリホスファゼン化合物、ポリホスファゼン−薬物コンジュゲート化合物およびその製造方法 | |
CN111012919B (zh) | 聚乙二醇化的icd诱导剂-ido抑制剂纳米缀合物及制备方法与应用 | |
US20210283257A1 (en) | Polymer composite for helicobacter pylori recognition and composition for photodynamic therapy comprising same | |
CN111298132B (zh) | 一种树状分子吉西他滨自组装纳米前药及其制备方法和应用 | |
CN109303780B (zh) | 一种还原响应型7-乙基-10-羟基喜树碱的两亲性聚合物药物前体及其制备方法 | |
JP6630293B2 (ja) | 鉄欠乏症の治療方法 | |
CN107951839B (zh) | 一种具有电荷可翻转的聚离子型胶束遮蔽体系及其制备方法 | |
WO2017206477A1 (zh) | 一种高分子ca4键合药物化合物及其制备方法 | |
CN106620714B (zh) | 7-乙基-10-羟基喜树碱-聚合物偶联药物及其纳米制剂制备方法 | |
WO2017049821A1 (zh) | 水溶性多西他赛抗癌药物化合物及其制备方法和应用 | |
JP2006117674A (ja) | 温度感応性及び生体適合性を有する両親媒性環状ホスファゼン三量体及びその製造方法 | |
CN109481695B (zh) | 一种具有pH响应的顺式-二氯二氨合铂配合物、其制备方法及应用 | |
JP6817930B2 (ja) | 免疫細胞のトラッキング方法 | |
WO2011044824A1 (zh) | 一种去氧鬼臼毒素环糊精包合物、其制法及抗癌用途 | |
CN111116614B (zh) | 免疫调节因子与紫杉烷的共价链接物及其白蛋白纳米制剂及制备方法 | |
KR20120126356A (ko) | 양친성 저분자량 히알루론산 복합체를 포함하는 나노 입자 및 그의 제조 방법 | |
CN110152011B (zh) | 一种免疫调节因子与紫杉烷的共价链接物及其白蛋白纳米制剂 | |
CN113750255B (zh) | 环境响应型透明质酸-鬼臼毒素前药胶束及其制备方法和应用 | |
WO2016078577A1 (zh) | 聚合物修饰的丹参酮i化合物或其纳米胶束、其制备方法和用途 | |
KR20150001693A (ko) | 헤파린-도세탁셀-토로콜산 접합체로 이루어진 표적성이 향상된 수용성 항암제 및 그의 제조방법 | |
CN118001240A (zh) | 一种鬼臼毒素-9-芴甲醇小分子前药纳米粒及其制备方法、应用 | |
JP2023516765A (ja) | 両親媒性アルギネート-オレイン酸高分子およびその製造方法 | |
CN118203671A (zh) | 一种基于电荷组装并具有响应性的纳米药物组合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180709 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180709 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190604 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190904 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191023 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20191023 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191126 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191206 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6630293 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |